Nightstar Therapeutics (NASDAQ:NITE) – Investment analysts at Leerink Swann issued their Q2 2018 earnings per share estimates for shares of Nightstar Therapeutics in a research note issued on Wednesday, April 11th. Leerink Swann analyst J. Schwartz anticipates that the company will post earnings per share of ($0.77) for the quarter. Leerink Swann also issued estimates for Nightstar Therapeutics’ Q4 2018 earnings at ($0.88) EPS, FY2018 earnings at ($1.66) EPS and FY2019 earnings at ($1.75) EPS.
Other equities research analysts have also recently issued reports about the stock. Chardan Capital initiated coverage on shares of Nightstar Therapeutics in a research report on Wednesday, January 3rd. They set a “buy” rating and a $40.00 price objective for the company. Mizuho initiated coverage on shares of Nightstar Therapeutics in a research report on Tuesday, February 27th. They set a “buy” rating and a $20.00 price objective for the company. Wedbush reaffirmed an “outperform” rating and set a $31.00 price objective on shares of Nightstar Therapeutics in a research report on Wednesday, March 7th. Finally, Zacks Investment Research cut shares of Nightstar Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, April 7th. One equities research analyst has rated the stock with a sell rating and six have issued a buy rating to the stock. Nightstar Therapeutics has an average rating of “Buy” and a consensus price target of $28.50.
A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Essex Investment Management Co. LLC purchased a new stake in Nightstar Therapeutics in the fourth quarter valued at $1,771,000. Ameriprise Financial Inc. purchased a new stake in Nightstar Therapeutics in the third quarter valued at $5,761,000. Finally, Nationwide Fund Advisors purchased a new stake in Nightstar Therapeutics in the third quarter valued at $1,196,000. 29.06% of the stock is owned by hedge funds and other institutional investors.
Nightstar Therapeutics Company Profile
Nightstar Therapeutics plc, a clinical-stage gene therapy company, focuses on developing and commercializing novel one-time treatments for patients suffering from rare inherited retinal diseases in the United Kingdom. The company's lead product candidate includes NSR-REP1, a candidate that has completed Phase 1/2 clinical trial for the treatment of patients with choroideremia.
Receive News & Ratings for Nightstar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nightstar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.